Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?

Executive Summary

Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.

You may also be interested in...



Apotex’s Generic Approvals Delayed By FDA Paperwork Snafu, Lawsuit Says

The agency’s “inexcusable delay” in granting final approval of Apotex’s ANDAs for Avapro and Avalide has caused the company to “fall fatally behind” in the marketplace now that 180-day exclusivity for the antihypertensive agents has expired, the manufacturer alleges.

Apotex Seeks Restitution For FDA Import Alert Before World Bank’s Arbitration Arm

Apotex claims an FDA import alert on two of its facilities caused damages in excess of $520 million; its complaint alleging U.S. government violation of NAFTA is the second it has brought before the International Centre for Settlement of Investment Disputes.

India's Race For Lipitor: More Than Five Players May Blunt Generic Gains In Post-Exclusivity Period

MUMBAI - Two years after Pfizer Inc. filed a patent infringement lawsuit against India's Dr. Reddy's Laboratories Ltd. in a bid to ward off threats to its blockbuster brand Lipitor (atorvastatin), the two companies filed a joint motion Aug. 19 to dismiss the case at the U.S. District Court of Delaware. The case was dismissed Aug. 29 but the terms and conditions of the settlement and a likely launch date for the generic versions of Dr. Reddy's product were not disclosed

Related Content

Topics

UsernamePublicRestriction

Register

PS053399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel